Skip to main content

HomeMelanotan IILegal status

Educational — Not Legal AdviceReviewed

Is Melanotan II legal? FDA status and US regulatory standing

Current status

Compounding nomination withdrawn. Melanotan II was nominated for the FDA bulk drug substances compounding list and was previously placed in a safety-review category before the nomination was withdrawn, so it does not appear on the current bulk substances lists.

Primary source: www.fda.gov

Federal legal status

FDA approval status

Melanotan II was nominated for the FDA bulk drug substances compounding list and was previously placed in a safety-review category before the nomination was withdrawn, so it does not appear on the current bulk substances lists. Not FDA-approved. Not to be confused with bremelanotide (PT-141/Vyleesi, which is approved). No NDA. Sold illicitly as research chemical. FDA warns against injectable tanning products.

Also known as

MT-II · MT2 · Melanotan 2

Frequently asked questions

Is Melanotan II FDA approved?
Melanotan II was nominated for the FDA bulk drug substances compounding list and was previously placed in a safety-review category before the nomination was withdrawn, so it does not appear on the current bulk substances lists. Primary source linked on this page.
Is Melanotan II legal to buy?
Melanotan II is available in the U.S. as a research-use-only compound. It was nominated for the FDA bulk drug substances compounding list and was previously placed in a safety-review category before the nomination was withdrawn, so it does not appear on the current bulk substances lists. Sale for human consumption is not permitted.
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Content review: Regulatory status is sourced from the linked primary records and reviewed by the PeptideBase editorial team. This page is educational — not legal or medical advice. Last reviewed: .

Free newsletter

The Peptide Research Digest

Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.

No spam. Unsubscribe anytime. Privacy policy.

Free Guide

The Peptide Research Digest

Get our free provider vetting guide — plus weekly research briefings on peptide sourcing, COA verification, and clinical developments.

No spam.